Aficamten

Brand name: Myqorzo

X

Score X — Unknown Risk

There is inadequate information to classify the hepatotoxicity risk of this drug.

The drug may be recently introduced or rarely used in clinical medicine, with insufficient published safety data to assign a risk category.

Primary class Cardiovascular
Secondary class Hypertrophic cardiomyopathy
FDA approval 2025
Search another medication

No article link available. Search directly at livertox.nih.gov.